Aquestive's Anaphylm resubmission accepted, FDA sets March 2027 goal dateNov 3Quarterly updateAquestive Therapeutics, Inc.
FDA accepts Aquestive's Anaphylm NDA resubmission, sets March 2027 PDUFA dateOct 15Regulatory milestoneAquestive Therapeutics, Inc.
Eton licenses LIBERVANT buccal film from Aquestive for U.S. epilepsy marketOct 14M&AAquestive Therapeutics, Inc.Eton Pharmaceuticals, Inc.
Aquestive resubmits FDA application for Anaphylm epinephrine filmSep 17Clinical readoutAquestive Therapeutics, Inc.
Aquestive completes Anaphylm studies, keeps Q3 2026 NDA resubmission timelineAug 11Quarterly updateAquestive Therapeutics, Inc.
Aquestive reports positive human factors and PK data for Anaphylm ahead of NDA resubmissionAug 10Clinical readoutAquestive Therapeutics, Inc.